These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 37190184)

  • 1. Isogenic Mammary Models of Intraductal Carcinoma Reveal Progression to Invasiveness in the Absence of a Non-Obligatory In Situ Stage.
    Bernhardt SM; Mitchell E; Stamnes S; Hoffmann RJ; Calhoun A; Klug A; Russell TD; Pennock ND; Walker JM; Schedin P
    Cancers (Basel); 2023 Apr; 15(8):. PubMed ID: 37190184
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Myoepithelial cell differentiation markers in ductal carcinoma in situ progression.
    Russell TD; Jindal S; Agunbiade S; Gao D; Troxell M; Borges VF; Schedin P
    Am J Pathol; 2015 Nov; 185(11):3076-89. PubMed ID: 26343330
    [TBL] [Abstract][Full Text] [Related]  

  • 3. P63 and cytokeratin8/18 expression in breast, atypical ductal hyperplasia, ductal carcinoma in situ and invasive duct carcinoma.
    Shamloula MM; El-Shorbagy SH; Saied EM
    J Egypt Natl Canc Inst; 2007 Sep; 19(3):202-10. PubMed ID: 19190693
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor-associated myoepithelial cells promote the invasive progression of ductal carcinoma
    Lo PK; Zhang Y; Yao Y; Wolfson B; Yu J; Han SY; Duru N; Zhou Q
    J Biol Chem; 2017 Jul; 292(27):11466-11484. PubMed ID: 28512126
    [TBL] [Abstract][Full Text] [Related]  

  • 5. p63 Staining of myoepithelial cells in breast fine needle aspirates: a study of its role in differentiating in situ from invasive ductal carcinomas of the breast.
    Reis-Filho JS; Milanezi F; Amendoeira I; Albergaria A; Schmitt FC
    J Clin Pathol; 2002 Dec; 55(12):936-9. PubMed ID: 12461063
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An Organotypic Mammary Duct Model Capturing Matrix Mechanics-Dependent Ductal Carcinoma
    Kulwatno J; Gong X; DeVaux R; Herschkowitz JI; Mills KL
    Tissue Eng Part A; 2021 Apr; 27(7-8):454-466. PubMed ID: 33397202
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Myoepithelial Cells of Salivary Intercalated Duct-type Intraductal Carcinoma Are Neoplastic: A Study Using Combined Whole-slide Imaging, Immunofluorescence, and RET Fluorescence In Situ Hybridization.
    Bishop JA; Rooper LM; Sangoi AR; Gagan J; Thompson LDR; Inagaki H
    Am J Surg Pathol; 2021 Apr; 45(4):507-515. PubMed ID: 33086236
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phenotypic and Functional Characterization of Ductal Carcinoma In Situ-Associated Myoepithelial Cells.
    Rohilla M; Bal A; Singh G; Joshi K
    Clin Breast Cancer; 2015 Oct; 15(5):335-42. PubMed ID: 25700939
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glucocorticoids promote transition of ductal carcinoma in situ to invasive ductal carcinoma by inducing myoepithelial cell apoptosis.
    Zubeldia-Plazaola A; Recalde-Percaz L; Moragas N; Alcaraz M; Chen X; Mancino M; Fernández-Nogueira P; Prats de Puig M; Guzman F; Noguera-Castells A; López-Plana A; Enreig E; Carbó N; Almendro V; Gascón P; Bragado P; Fuster G
    Breast Cancer Res; 2018 Jul; 20(1):65. PubMed ID: 29973218
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Loss of myoepithelial calponin-1 characterizes high-risk ductal carcinoma in situ cases, which are further stratified by T cell composition.
    Mitchell E; Jindal S; Chan T; Narasimhan J; Sivagnanam S; Gray E; Chang YH; Weinmann S; Schedin P
    Mol Carcinog; 2020 Jul; 59(7):701-712. PubMed ID: 32134153
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Everolimus Inhibits the Progression of Ductal Carcinoma
    Chen G; Ding XF; Pressley K; Bouamar H; Wang B; Zheng G; Broome LE; Nazarullah A; Brenner AJ; Kaklamani V; Jatoi I; Sun LZ
    Clin Cancer Res; 2020 Mar; 26(6):1486-1496. PubMed ID: 31871301
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer.
    Allred DC; Clark GM; Molina R; Tandon AK; Schnitt SJ; Gilchrist KW; Osborne CK; Tormey DC; McGuire WL
    Hum Pathol; 1992 Sep; 23(9):974-9. PubMed ID: 1355464
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative Profiling of Metastatic 4T1- vs. Non-metastatic Py230-Based Mammary Tumors in an Intraductal Model for Triple-Negative Breast Cancer.
    Steenbrugge J; Vander Elst N; Demeyere K; De Wever O; Sanders NN; Van Den Broeck W; Dirix L; Van Laere S; Meyer E
    Front Immunol; 2019; 10():2928. PubMed ID: 31921184
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of clinicopathological characteristics and prognosis among patients with pure invasive ductal carcinoma, invasive ductal carcinoma coexisted with invasive micropapillary carcinoma, and invasive ductal carcinoma coexisted with ductal carcinoma in situ: A retrospective cohort study.
    Guan X; Xu G; Shi A; Zou Y; Zhan Y; Fan Z; Dong Y
    Medicine (Baltimore); 2020 Dec; 99(50):e23487. PubMed ID: 33327281
    [TBL] [Abstract][Full Text] [Related]  

  • 15. COX-2, p16 and Ki67 expression in DCIS, microinvasive and early invasive breast carcinoma with extensive intraductal component.
    Bartova M; Ondrias F; Muy-Kheng T; Kastner M; Singer Ch; Pohlodek K
    Bratisl Lek Listy; 2014; 115(7):445-51. PubMed ID: 25077370
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Silencing of HSulf-2 expression in MCF10DCIS.com cells attenuate ductal carcinoma in situ progression to invasive ductal carcinoma in vivo.
    Khurana A; McKean H; Kim H; Kim SH; mcguire J; Roberts LR; Goetz MP; Shridhar V
    Breast Cancer Res; 2012 Mar; 14(2):R43. PubMed ID: 22410125
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The value of immunohistochemical expression of Ki-67 and CD34 in differentiating ductal carcinoma in situ from ductal carcinoma in situ-like invasive breast cancer].
    Pan XY; Wu JK; Lang ZQ; Qu L; Jiang L
    Zhonghua Bing Li Xue Za Zhi; 2022 Sep; 51(9):838-842. PubMed ID: 36097899
    [No Abstract]   [Full Text] [Related]  

  • 18. Invasive ductal carcinoma with coexisting ductal carcinoma in situ (IDC/DCIS) versus pure invasive ductal carcinoma (IDC): a comparison of clinicopathological characteristics, molecular subtypes, and clinical outcomes.
    Goh CW; Wu J; Ding S; Lin C; Chen X; Huang O; Chen W; Li Y; Shen K; Zhu L
    J Cancer Res Clin Oncol; 2019 Jul; 145(7):1877-1886. PubMed ID: 31089799
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of Her2/neu, steroid receptors (ER and PR), Ki67 and p53 in invasive mammary ductal carcinoma associated with ductal carcinoma In Situ (DCIS) Versus invasive breast cancer alone.
    Mylonas I; Makovitzky J; Jeschke U; Briese V; Friese K; Gerber B
    Anticancer Res; 2005; 25(3A):1719-23. PubMed ID: 16033090
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genomic differences between pure ductal carcinoma in situ and synchronous ductal carcinoma in situ with invasive breast cancer.
    Kim SY; Jung SH; Kim MS; Baek IP; Lee SH; Kim TM; Chung YJ; Lee SH
    Oncotarget; 2015 Apr; 6(10):7597-607. PubMed ID: 25831047
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.